Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction

Sylvain Garciaz, Pierre-Yves Dumas, Pierre Peterlin, Daniel Morillo, Jose Miguel Torregrosa Diaz, Matthew Ulrickson, Agustin Penedo, Aude De Gassart, Emmanuel Valentin, Maelle Mairesse, George Saad, Patrick Brune, Katrien Lemmens, Noemi Angelosanto, Daniel Olive, Stephan Braun, Naval Daver, Abhishek Maiti

Blood (2025) 146 (Supplement 1): 652.

https://doi.org/10.1182/blood-2025-652

Published: 2025

Journal Articles

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study

Nirav Shah, Scott Huntington, David Lewis, Talha Munir, Graham Collins, Alvaro Alencar, Kim Linton, Zulfa Omer, Dima El-Sharkawi, Mary Gleeson, Pamela McKay, Jeanette Doorduijn, Jeffery Smith, Daniel Morillo, Pau Abrisqueta, Sarah Injac, Astrid Pulles

Blood (2025) 146 (Supplement 1): 5359.

https://doi.org/10.1182/blood-2025-5359

Published: 2025

Journal Articles

Promising efficacy of BI-1206, an antibody targeting FcγRIIB in combination with rituximab and acalabrutinib in R/R NHL patients NHL

Laura Fogliatto, Ana Cordeiro, Eva Domingo Domenech, Daniel Morillo, Augustin Penedo Coello, Erika Bågeman, Danijela Lindahl, Ingrid Karlsson, Linda Mårtensson, Zinnia Parra Guillen, Dmytro Piliuhin, Karin Risberg Handeland, Ingrid Teige, Johan Wallin, Björn Frendeus, Andres McAllister

Blood (2025) 146 (Supplement 1): 5349.

https://doi.org/10.1182/blood-2025-5349

Published: 2025

Journal Articles

Effectiveness of comprehensive geriatric assessment (CGA) in older patients with diffuse large B-cell lymphoma (DLBCL) and the impact of frailty in treatment tolerability and survival in a prospective, multicenter study.

Raul Cordoba, Sergio Ramos, Juan Carlos Caballero, Eva Castillo, Ignacio Mahillo, Maria-Angeles Perez, Daniel Morillo, Laura Solán Blanco, Laura Pardo, Ana-Carolina Miranda, Maria-Gabriela Salvatierra, Cristina Gonzalez de Villaumbrosia, Myriam Rodriguez-Couso, Javier Martinez-Peromingo, Ana-Isabel Hormigo

Blood (2025) 146 (Supplement 1): 4508.

https://doi.org/10.1182/blood-2025-4508

Published: 2025

Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

Blood (2025) 146 (Supplement 1): 479.

https://doi.org/10.1182/blood-2025-479

Published: 2025

Journal Articles

Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial

Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua Brody, Daniel Morillo, Kim Linton, Sylvia Snauwaert, Michael Roost Clausen, Raul Cordoba, Toshihiko Oki, Monica Wielgos-Bonvallet, Mina Khoshdeli, Yi Hao, Jennifer Marek, Malene Risum, David Belada

Blood (2025) 146 (Supplement 1): 1955.

https://doi.org/10.1182/blood-2025-1955

Published: 2025

Journal Articles

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Jenny O'Nions, Andrew Wei, Jordi Esteve, Ibrahim Aldoss, Ana Alfonso-Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Nikki Daskalakis, Matteo Della Porta, Hartmut Döhner, Amber D'Souza, James Dugan, Amir Fathi, Pasquale Fedele, Lucille Ferrante, Rachel Kobos, Ana Garrido, Sara Garrido Paniagua, Christina Drenberg Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Danielle Trancucci, Naa Sackey, Madlen Jentzsch, Hagop Kantarjian, Marina Konopleva, Jan Krönke, Marie Luise Hütter-Krönke, Christina Loefgren, Oliver Lomas, Valentina Mancini, Daniel Morillo, Kathryn Packman, Cristina Papayannidis, Christian Recher, Christoph Röllig, Olga Salamero, Prathap Nagaraja Shastri, Tim Sauer, Dr. Emma Searle, Natalia Tovar, Nicolas Vallet, Lachlin Vaughan, Paresh Vyas, Uwe Platzbecker, Sylvain Garciaz

Blood (2025) 146 (Supplement 1): 5200.

https://doi.org/10.1182/blood-2025-5200

Published: 2025

Journal Articles

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Hartmut Döhner, Andre Schuh, Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso-Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Nikki Daskalakis, Matteo Della Porta, Amber D'Souza, James Dugan, Jordi Esteve, Amir Fathi, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Olga Salamero, Christina Drenberg Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop Kantarjian, Marina Konopleva, Jan Krönke, Marie Luise Hütter-Krönke, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Daniel Morillo, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sara Garrido Paniagua, Naa Sackey, Tim Sauer, Dr. Emma Searle, Prathap Nagaraja Shastri, Danielle Trancucci, Natalia Tovar, Nicolas Vallet, Lachlin Vaughan, Paresh Vyas, Andrew Wei, Christoph Röllig

Blood (2025) 146 (Supplement 1): 5199.

https://doi.org/10.1182/blood-2025-5199

Published: 2025

Journal Articles

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5757.

https://doi.org/10.1182/blood-2025-5757

Published: 2025

Journal Articles

Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population

Joshua Brody, David Belada, Daniel Morillo, Régis Costello, Marek Trneny, Sven de Vos, Gerardo Musuraca, Umberto Vitolo, David Lewis, Jacob Christensen, Marcel Nijland, Tony Jiang, Kubra Karagoz, Andrew J. Steele, Jennifer Marek, Liwei Wang, Malene Risum, Raul Cordoba, Judit Jørgensen

Blood (2025) 146 (Supplement 1): 3736.

https://doi.org/10.1182/blood-2025-3736

Published: 2025

Journal Articles

Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years

Blood (2025) 146 (Supplement 1): 701.

https://doi.org/10.1182/blood-2025-701

Published: 2025

Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results

Julio Chavez, Jason Westin, Javier Munoz, Emmanuel Bachy, Judit Jørgensen, Guilherme Perini, Daniel Morillo, Abel Costa, Parth Rao, Berengere De Moucheron, Gang Yang, Soraya Carrancio, Akshay Sudhindra, Michael Pourdehnad, Jessica Voetsch, Serena Perna, Jean-Marie Michot

Blood (2025) 146 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2025-1006

Published: 2025

Journal Articles

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Blood blood.2025029360.

https://doi.org/10.1182/blood.2025029360

Published: 2025

Includes: Supplemental data

Journal Articles

Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies

Blood (2024) 144 (Supplement 1): 495.

https://doi.org/10.1182/blood-2024-200181

Published: 2024

Journal Articles

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Martin Curtis, Nikki Daskalakis, Matteo Giovanni Della Porta, Hartmut Döhner, Amber D'Souza, James P. Dugan, Jordi Esteve Reyner, Matthew Exum, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Min Chul Kwon, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Giovanni Martinelli, Daniel Morillo Giles, Joseph Murphy, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sravanti Rangaraju, Christoph Röllig, Olga Salamero, Madhu Sanga, Tim Sauer, Emma Searle, Natalia Tovar, Trevor Tucker, Nicolas Vallet, Lachlin Vaughan, Gala Vega, Paresh Vyas, Andrew Wei

Blood (2024) 144 (Supplement 1): 215.

https://doi.org/10.1182/blood-2024-207072

Published: 2024

Journal Articles

Open-Label Phase 1 Study to Evaluate the Safety of SGN-35T in Patients with Relapsed/Refractory CD30-Expressing Lymphoid Malignancies (SGN35T-001; trial in progress)

Tatyana Feldman, Hun Ju Lee, Gizelle Popradi, Graham P. Collins, Daniel Morillo, Ming Jin Yan, Tara Chen, Youn H. Kim

Blood (2024) 144 (Supplement 1): 6356.

https://doi.org/10.1182/blood-2024-200265

Published: 2024

Journal Articles

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study

Julio C. Chavez, Guilherme Fleury Perini, Loretta Nastoupil, Judit Mészáros Joergensen, Pierre Bories, Bijou Fontanet, Pier Luigi Zinzani, Javier Munoz, Daniel Morillo Giles, Cecilia Carpio, Abel Costa, Won Seog Kim, Parth Rao, Bérengère de Moucheron, Yang Gang, Carla Guarinos, Akshay Sudhindra, Michael Pourdehnad, Jean-Marie Michot

Blood (2024) 144 (Supplement 1): 3018.

https://doi.org/10.1182/blood-2024-203131

Published: 2024

Journal Articles

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Antonio Gutiérrez, Izaskun Zeberio, Pilar Martinez-Barranco, Francisco Javier Peñalver, Sandra Pérez, Daniel Morillo, Xabier Mart N Martitegui, Concepción Nicolás, Ainara Ferrero, Ana Jiménez Ubieto, Mariana Bastos-Oreiro, Julio Dávila-Valls, Maria Victoria Calle Gordo, María Pérez Sala, Guillermo Rodríguez Garcia, Aranzazu Alonso Alonso, Ana Garcia Noblejas, Diana Sanchez Arguello, Teresa Knight Asorey, Maria Angeles Fernandez Fernandez, Javier López Marin, Jaime Perez de Oteyza, Sonia González De Villambrosia, Elena Perez Ceballos, Alejandro Marin, Belén Navarro, Ruben Fernandez Alvarez, Pilar Gómez, Jose Antonio Hueso, Maria Jesus Penarrubia Ponce, Pilar Bravo, Daniel García Belmonte, Haridian De La Nuez Melian, Sara Nistal, Pau Abrisqueta Costa, Fernanda Ibañez, Luis Palomera, Eva Donato, Andrea Provencio Rincon, Maria Stefania Infante, Eva Gonzalez Barca

Blood (2024) 144 (Supplement 1): 2356.

https://doi.org/10.1182/blood-2024-210868

Published: 2024

Journal Articles

ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction

Abhishek Maiti, Pierre Yves Dumas, Pierre Peterlin, Daniel Morillo, Jose Torregrosa, Paul B. Koller, Maelle Mairesse, Patrick Brune, Emmanuel Valenitn, Aude De Gassart, Katrien Lemmens, Daniel Olive, Naval Daver, Stephan Braun, Sylvain Garciaz

Blood (2024) 144 (Supplement 1): 2876.

https://doi.org/10.1182/blood-2024-193493

Published: 2024

Journal Articles

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Sumit Madan, Caitlin L. Costello, Brea Lipe, Andrew J. Cowan, Eva Medvedova, Jens Hillengass, P. Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, Henning Schade, Salomon Manier, Yifah Yaron, Banmeet Anand, Al-Ola Abdallah

Blood (2023) 142 (Supplement 1): 1012.

https://doi.org/10.1182/blood-2023-182345

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study

Promising efficacy of BI-1206, an antibody targeting FcγRIIB in combination with rituximab and acalabrutinib in R/R NHL patients NHL

Effectiveness of comprehensive geriatric assessment (CGA) in older patients with diffuse large B-cell lymphoma (DLBCL) and the impact of frailty in treatment tolerability and survival in a prospective, multicenter study.

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population

Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Open-Label Phase 1 Study to Evaluate the Safety of SGN-35T in Patients with Relapsed/Refractory CD30-Expressing Lymphoid Malignancies (SGN35T-001; trial in progress)

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only